Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch

New investor Horizon 3 Healthcare led the round, which was supported by the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders